myFibroScan vs SMARTDM2

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.

The management of outpatient antihyperglycemic regimens for patients with type 2 diabetes is complicated. This app is designed to synthesize treatment pathway guidelines developed by the American Diabetes Association, the American Association of Clinical Endocrinologists / American College of Endocrinology, and the Emory University Diabetes Council. Based on patient-specific factors that you select, a weighted list of medication options is sorted and presented. Designed for use by healthcare professionals. We have no relationship with nor has the app been endorsed by the American Diabetes Association, the American Association of Clinical Endocrinologists or the American College of Endocrinology. Results from the app should not be considered medical advice: individual patient factors not accounted for in the app may influence management decisions; medical evidence and guidelines may change ahead of updates to the app; regardless of best efforts, errors may be present in the app. Consult your doctor before making any changes to your medication regimen.